REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options, RSUs and PSUs and PDMR Dealing

MaxCyteAnnouncement

20/03/2024 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST6067Ha&default-theme=true

RNS Number : 6067H  MaxCyte, Inc.  20 March 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options, RSUs and PSUs and PDMR Dealing

 

Rockville, Maryland - 20 March 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and innovative bioprocessing applications,
announces that on 15 March 2024, a target grant of 400,000 performance stock
units ("PSUs") were granted to Maher Masoud, President, Chief Executive
Officer and Director of the Company, and 225,000 options in respect of common
stock in the Company, 81,250 restricted stock units ("RSUs") and a target
grant of 31,250 PSUs were granted to Douglas Swirsky, Chief Financial Officer
of the Company.

 

Details of the stock options

The options granted to Mr. Swirsky vest as to 25% of the total grant on the
first anniversary of the date of grant, and the remaining 75% vest in 36 equal
monthly instalments thereafter.

 

The options granted to Mr. Swirsky have an exercise period of 10 years from
date of grant, at which time they will expire, and have an exercise price of
$4.31, being equal to the closing price of MaxCyte's common stock on Nasdaq on
15 March 2024.

 

Details of the RSUs

Each RSU represents the contingent right to receive one share of common stock
in the Company. The RSUs granted to Mr. Swirsky vest as to 25% on each of the
first, second, third and fourth anniversary of the date of grant. No exercise
price is payable on vesting or settlement of the RSUs.

 

Details of the PSUs

Each PSU represents the contingent right to receive one share of common stock
in the Company upon the achievement of specified performance metrics. The PSU
grants made to Messrs. Masoud and Swirsky on 15 March 2024 represent a number
of shares of common stock to be earned if the target level of performance is
achieved. The performance period continues through 31 December 2026, after
which time the level of performance achievement will be determined by the
Board of Directors or an authorized committee thereof.  The actual number of
shares of common stock underlying the PSUs to be earned will be between 0% and
125% of the target number of PSUs, depending on the level of achievement of
such performance metrics. No exercise price is payable on the vesting or
settlement of the PSUs.

 

The information in the tables below is provided in accordance with the
requirements of the UK Market Abuse Regulation.

 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology platform, as
well as scientific, technical, and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/i/flow/login?redirect_after_login=%2FMaxCyte_info) and
LinkedIn (https://www.linkedin.com/company/maxcyte-inc-/) .

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Gordon                                +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Consilium                                 maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Mary-Jane Elliott

 Chris Welsh

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Maher Masoud

 2    Reason for the notification

 a)   Position/status                                              President, CEO and Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Grant of PSUs in respect of common stock

 c)   Price(s) and volume(s)

                                                                                         Exercise Price(s)     Volume(s)
                                                                                         N/A                   400,000 PSUs

 d)   Aggregated information

      - Aggregated volume                                          400,000 PSUs (up to 500,000 shares of common stock if performance metrics are
                                                                   fully satisfied)

      - Price                                                      N/A
 e)   Date of the transaction                                      15 March, 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Douglas Swirsky

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Grant of options, RSUs and PSUs in respect of common stock

 c)   Price(s) and volume(s)                                                             Options:

                                                                                         Exercise Price(s)     Volume(s)
                                                                                         $4.31                 225,000

                                                                   RSUs:

      Exercise Price(s)                                            Volume(s)
                                                                                         N/A                   81,250

                                                                   PSUs:

      Exercise Price(s)                                            Volume(s)
                                                                   N/A                   31,250

 d)   Aggregated information

      - Aggregated volume                                          225,000 options, 81,250 RSUs and 31,250 PSUs (up to 345,313 shares of common
                                                                   stock if performance metrics for the PSUs are fully satisfied)

      - Price                                                      $4.31 for the options; no exercise price for the RSUs and PSUs

 e)   Date of the transaction                                      15 March, 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHURARRSSUOUAR